Objective response to immune checkpoint inhibitor therapy in NRAS-mutant melanoma: A systematic review and meta-analysis

INTRODUCTION: NRAS mutations are common in melanoma and confer a worse prognosis. Although most patients with metastatic melanoma receive immune checkpoint inhibitors (ICIs), the impact of NRAS mutational status on their efficacy remains under debate. METHODS: We performed a comprehensive literature...

Descripción completa

Detalles Bibliográficos
Autores principales: Jaeger, Zachary J., Raval, Neel S., Maverakis, Natalia K. A., Chen, David Y., Ansstas, George, Hardi, Angela, Cornelius, Lynn A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979544/
https://www.ncbi.nlm.nih.gov/pubmed/36873887
http://dx.doi.org/10.3389/fmed.2023.1090737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979544/
https://www.ncbi.nlm.nih.gov/pubmed/36873887
http://dx.doi.org/10.3389/fmed.2023.1090737

Ejemplares similares